Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

内科学 危险系数 医学 白血病 细胞遗传学 肿瘤科 急性淋巴细胞白血病 置信区间 免疫学 生物 淋巴细胞白血病 染色体 生物化学 基因
作者
Allison Barz Leahy,Kaitlin J. Devine,Yimei Li,Hongyan Liu,Regina M. Myers,Amanda M. DiNofia,Lisa Wray,Susan R. Rheingold,Colleen A. Callahan,Diane Baniewicz,Maria Patino,Haley M. Newman,Stephen P. Hunger,Stephan A. Grupp,David Maxwell Barrett,Shannon L. Maude
出处
期刊:Blood [Elsevier BV]
卷期号:139 (14): 2173-2185 被引量:120
标识
DOI:10.1182/blood.2021012727
摘要

Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential outcomes mediated by leukemia cytogenetics. We identified children and young adults with relapsed/refractory CD19+ ALL/lymphoblastic lymphoma treated on 5 CD19-directed CAR T-cell (CTL019 or humanized CART19) clinical trials or with commercial tisagenlecleucel from April 2012 to April 2019. Patients were hierarchically categorized according to leukemia cytogenetics: High-risk lesions were defined as KMT2A (MLL) rearrangements, Philadelphia chromosome (Ph+), Ph-like, hypodiploidy, or TCF3/HLF; favorable as hyperdiploidy or ETV6/RUNX1; and intermediate as iAMP21, IKZF1 deletion, or TCF3/PBX1. Of 231 patients aged 1 to 29, 74 (32%) were categorized as high risk, 28 (12%) as intermediate, 43 (19%) as favorable, and 86 (37%) as uninformative. Overall complete remission rate was 94%, with no difference between strata. There was no difference in relapse-free survival (RFS; P = .8112), with 2-year RFS for the high-risk group of 63% (95% confidence interval [CI], 52-77). There was similarly no difference seen in overall survival (OS) (P = .5488), with 2-year OS for the high-risk group of 70% (95% CI, 60-82). For patients with KMT2A-rearranged infant ALL (n = 13), 2-year RFS was 67% (95% CI, 45-99), and OS was 62% (95% CI, 40-95), with multivariable analysis demonstrating no increased risk of relapse (hazard ratio, 0.70; 95% CI, 0.21-2.90; P = .7040) but a higher proportion of relapses associated with myeloid lineage switch and a 3.6-fold increased risk of all-cause death (95% CI, 1.04-12.75; P = .0434). CTL019/huCART19/tisagenlecleucel are effective at achieving durable remissions across cytogenetic categories. Relapsed/refractory patients with high-risk cytogenetics, including KMT2A-rearranged infant ALL, demonstrated high RFS and OS probabilities at 2 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
粉刷匠完成签到,获得积分10
刚刚
杨莹完成签到,获得积分10
刚刚
洁净灵松完成签到 ,获得积分10
刚刚
快乐的砖家完成签到 ,获得积分10
1秒前
天天完成签到,获得积分10
1秒前
整齐的书雁完成签到,获得积分10
1秒前
www发布了新的文献求助10
2秒前
2秒前
无所谓完成签到,获得积分10
2秒前
九局下半发布了新的文献求助10
2秒前
MQ_Ningbo完成签到,获得积分10
3秒前
认真觅荷完成签到 ,获得积分10
3秒前
呜呼发布了新的文献求助10
3秒前
赵洋萍完成签到 ,获得积分10
3秒前
4秒前
LOAD完成签到,获得积分10
4秒前
棟糖完成签到,获得积分10
4秒前
Anla的应助被Bismarck采纳,获得10
4秒前
4秒前
森森芊芊完成签到,获得积分10
5秒前
研友_VZG7GZ的应助被MusChen采纳,获得10
5秒前
5秒前
怒马完成签到,获得积分10
6秒前
萝卜公主完成签到,获得积分10
6秒前
6秒前
zhi完成签到,获得积分10
6秒前
Lucas的应助被oucedv采纳,获得10
7秒前
马可菠萝包完成签到 ,获得积分10
7秒前
Owen的应助被JWD采纳,获得10
7秒前
chrysan完成签到,获得积分10
7秒前
Evan123完成签到,获得积分10
7秒前
7秒前
8秒前
蘑菇菇完成签到,获得积分10
8秒前
玛卡巴卡完成签到,获得积分10
8秒前
李健的应助被热爱科研的小刘采纳,获得10
8秒前
wonderingria完成签到,获得积分10
9秒前
menghuigucha完成签到,获得积分10
9秒前
江sir完成签到,获得积分10
9秒前
和谐雪曼完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152354
求助须知:如何正确求助?哪些是违规求助? 9549023
关于积分的说明 21690364
捐赠科研通 7740603
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550379
邀请新用户注册赠送积分活动 2468675